Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin infiltration for chronic breast-region pain and upper limb dysfunction after breast cancer treatment
NL-OMON26807Not yet recruiting
- Sponsor
- UZ Leuven
- Start
- Feb 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Trial of neuronox and saline in persistent pain after breast cancer treatment (PPBCT) (2 arms), sponsored by UZ Leuven. Primary endpoint: Evolution of pain at the breast region. Planned start Feb 2015; status: not yet recruiting.
02
Drugs
neuronoxsaline
03
Conditions
persistent pain after breast cancer treatment (PPBCT)
Beyond the preview
Go deeper on NL-OMON26807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26807.